홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ANVS
#3492
Annovis Bio, Inc.
2.6
9
-2.54%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-2.54%
월간 변동
-9.12%
6달 변화
+14.47%
년간 변동율
+46.20%
이전 종가
2.7
6
Open
2.6
6
Bid
Ask
Low
2.6
6
High
2.6
9
양
28
마켓
주식
헬스케어
ANVS
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
13.8 M
19.49 M
19.49 M
19.49 M
26.5 M
—
Valuation ratios
Enterprise value
98.57 M
87.46 M
6.99 M
25.15 M
39.57 M
159.19 M
Price to earnings ratio
-1.71
-2.18
-0.74
-1.4
-1.74
-6.06
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-3.61
-2.81
-0.89
-1.31
-1.31
-6.32
Price to book ratio
-10.34
6.61
0.59
0.6
0.55
8.36
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.88
-0.42
-0.21
-0.29
-0.42
-1.34
Return on equity %
-1.79
-0.63
-0.23
-0.34
-0.55
-1.75
Return on invested capital %
7 128.56
—
-580.57
519.35
-2 240.34
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
2.38
2.83
9.03
6.26
4.2
22.32
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.28
-0.68
-0.46
-0.28
-0.18
-1.6
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.1
0.87
1.27
0.93
0.81
3.88
Net current asset value per share
1.12
0.9
1.3
0.95
0.83
3.98
Tangible book value per share
0.62
0.76
1.38
0.99
0.7
3.83
Working capital per share
0.65
0.58
1.15
0.8
0.63
3.17
Book value per share
0.62
0.76
1.38
0.99
0.7
3.83
뉴스
아노비스 바이오, 2026년 1월 파킨슨병 장기 약물 연구 개시
Annovis Bio to launch long-term Parkinson’s drug study in January
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops
Annovis Bio 이사 Hoffman, 193,794달러 상당 주식 매수
Annovis Bio director Hoffman buys $193,794 in shares
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling
아노비스 바이오 이사 Hoffman, ANVS 주식 69.9천 달러 매입
Annovis Bio director Hoffman buys $69.9k in ANVS stock
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS)
Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion
Annovis Bio raises $3.4 million in registered direct offering